{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:53:23Z","timestamp":1786982003137,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11523-024-01049-w","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T23:09:33Z","timestamp":1713654573000},"page":"343-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed\/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone"],"prefix":"10.1007","volume":"19","clinical-trial-number":[{"clinical-trial-number":"nct03110822","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1587-6104","authenticated-orcid":false,"given":"James R.","family":"Berenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Limon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahmineh","family":"Safaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Moezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrooz","family":"Eshaghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Brobeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Eades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bujarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohana","family":"Sebhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Del Dosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vescio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"issue":"1","key":"1049_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3. https:\/\/doi.org\/10.3390\/medsci9010003.","journal-title":"Med Sci"},{"key":"1049_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017;31:1915\u201321. https:\/\/doi.org\/10.1038\/leu.2016.380.","journal-title":"Leukemia"},{"key":"1049_CR3","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443\u20138. https:\/\/doi.org\/10.1038\/leu.2017.138.","journal-title":"Leukemia"},{"issue":"23","key":"1049_CR4","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.3390\/cancers14235759","volume":"14","author":"J Mina\u0159\u00edk","year":"2022","unstructured":"Mina\u0159\u00edk J, \u0160ev\u010d\u00edkov\u00e1 S. Immunomodulatory agents for multiple myeloma. Cancers (Basel). 2022;14(23):5759. https:\/\/doi.org\/10.3390\/cancers14235759.","journal-title":"Cancers (Basel)."},{"key":"1049_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12185-016-2073-4","volume":"104","author":"T Ito","year":"2016","unstructured":"Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs History of immunomodulatory drugs (IMiDs). Int J Hematol. 2016;104:293\u20139. https:\/\/doi.org\/10.1007\/s12185-016-2073-4.","journal-title":"Int J Hematol"},{"issue":"1","key":"1049_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/tcrm.s1445","volume":"4","author":"T Hideshima","year":"2008","unstructured":"Hideshima T, Raje N, Richardson PG, Anderson KC. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008;4(1):129\u201336. https:\/\/doi.org\/10.2147\/tcrm.s1445.","journal-title":"Ther Clin Risk Manag"},{"key":"1049_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.exphem.2020.09.196","volume":"91","author":"S Martinez-H\u00f8yer","year":"2020","unstructured":"Martinez-H\u00f8yer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020;91:22\u201331. https:\/\/doi.org\/10.1016\/j.exphem.2020.09.196.","journal-title":"Exp Hematol"},{"issue":"2","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","volume":"9","author":"YX Zhu","year":"2019","unstructured":"Zhu YX, Shi CX, Bruins LA, Wang X, Riggs DL, Porter B, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9(2):19. https:\/\/doi.org\/10.1038\/s41408-019-0173-0.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1049_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/2050-7771-1-5","volume":"1","author":"M Furqan","year":"2013","unstructured":"Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013;1(1):5. https:\/\/doi.org\/10.1186\/2050-7771-1-5.","journal-title":"Biomark Res."},{"issue":"20","key":"1049_CR10","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood.2019004332","volume":"136","author":"D Ogiya","year":"2020","unstructured":"Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai Y-T, et al. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020;136(20):2334\u201345. https:\/\/doi.org\/10.1182\/blood.2019004332.","journal-title":"Blood"},{"key":"1049_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23:10\u201324. https:\/\/doi.org\/10.1038\/leu.2008.259.","journal-title":"Leukemia"},{"key":"1049_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1593\/neo.91192","volume":"12","author":"J Li","year":"2010","unstructured":"Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, et al. INCB16562, a JAK1\/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia. 2010;12:28\u201338. https:\/\/doi.org\/10.1593\/neo.91192.","journal-title":"Neoplasia"},{"key":"1049_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00277-019-03595-0","volume":"98","author":"E Sanchez","year":"2019","unstructured":"Sanchez E, Li M, Patil S, Soof CM, Nosrati JD, Schlossberg RE, et al. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. Ann Hematol. 2019;98:691\u2013703. https:\/\/doi.org\/10.1007\/s00277-019-03595-0.","journal-title":"Ann Hematol"},{"key":"1049_CR14","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.24911","volume":"2","author":"N Gupta","year":"2013","unstructured":"Gupta N, Mayer D. Interaction of JAK with steroid receptor function. JAKSTAT. 2013;2: e24911. https:\/\/doi.org\/10.4161\/jkst.24911.","journal-title":"JAKSTAT."},{"key":"1049_CR15","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/leu.2011.175","volume":"25","author":"KA Monaghan","year":"2011","unstructured":"Monaghan KA, Khong T, Burns CJ, Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia. 2011;25:1891\u20139. https:\/\/doi.org\/10.1038\/leu.2011.175.","journal-title":"Leukemia"},{"key":"1049_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ajh.21785","volume":"85","author":"V Ramakrishnan","year":"2010","unstructured":"Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, et al. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD451 myeloma cells. Am J Hematol. 2010;85:675\u201386. https:\/\/doi.org\/10.1002\/ajh.21785.","journal-title":"Am J Hematol"},{"key":"1049_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/hon.3071","volume":"41","author":"N Xu","year":"2023","unstructured":"Xu N, Yu E, Ng N, Li M, Bujarski S, Hekmati A, et al. The JAK1\/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma. Hematol Oncol. 2023;41:578\u201382. https:\/\/doi.org\/10.1002\/hon.3071.","journal-title":"Hematol Oncol"},{"issue":"21","key":"1049_CR18","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood.V124.21.2114.2114","volume":"124","author":"H Chen","year":"2014","unstructured":"Chen H, Sanchez E, Li M, Wang C, Gillespie A, Shvartsur A, et al. Anti-myeloma activity by the combination of the JAK2 inhibitor ruxolitinib with lenalidomide and corticosteroids. Blood. 2014;124(21):2114. https:\/\/doi.org\/10.1182\/blood.V124.21.2114.2114.","journal-title":"Blood"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bjh.17282","volume":"192","author":"H Chen","year":"2020","unstructured":"Chen H, Li M, Ng N, Yu E, Bujarski S, Yin Z, et al. Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma. Br J Haematol. 2020;192:568\u201376. https:\/\/doi.org\/10.1111\/bjh.17282.","journal-title":"Br J Haematol"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/bjh.16158","volume":"188","author":"H Chen","year":"2020","unstructured":"Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, et al. JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression. Br J Haematol. 2020;188:283\u201394. https:\/\/doi.org\/10.1111\/bjh.16158.","journal-title":"Br J Haematol"},{"key":"1049_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40265-015-0351-8","volume":"75","author":"GL Plosker","year":"2015","unstructured":"Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis. Drugs. 2015;75:297\u2013308. https:\/\/doi.org\/10.1007\/s40265-015-0351-8.","journal-title":"Drugs"},{"key":"1049_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/nejmoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335. https:\/\/doi.org\/10.1056\/nejmoa1409002.","journal-title":"N Engl J Med"},{"key":"1049_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.canlet.2017.06.016","volume":"403","author":"MB De Oliveira","year":"2017","unstructured":"De Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson FG, De Carvalho MF, et al. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: a rationale for JAK\/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017;403:206\u201315. https:\/\/doi.org\/10.1016\/j.canlet.2017.06.016.","journal-title":"Cancer Lett"},{"key":"1049_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0960-0760(02)00223-6","volume":"82","author":"M Krasil\u2019nikov","year":"2002","unstructured":"Krasil\u2019nikov M, Shatskaya V. Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J Steroid Biochem Mol Biol. 2002;82:369\u201376.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1049_CR25","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0091270010389469","volume":"51","author":"JG Shi","year":"2011","unstructured":"Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51:1644\u201354. https:\/\/doi.org\/10.1177\/0091270010389469.","journal-title":"J Clin Pharmacol"},{"key":"1049_CR26","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","volume":"82","author":"H Uchiyama","year":"1993","unstructured":"Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712\u201320.","journal-title":"Blood"},{"issue":"3","key":"1049_CR27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","volume":"87","author":"D Chauhan","year":"1996","unstructured":"Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K-L, Libermann TA, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-KB. Blood. 1996;87(3):1104\u201312.","journal-title":"Blood"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/bjc.2013.186","volume":"108","author":"S Ma\u00efga","year":"2013","unstructured":"Ma\u00efga S, Gomez-Bougie P, Bonnaud S, Gratas C, Moreau P, Le Gouill S, et al. Paradoxical effect of lenalidomide on cytokine\/growth factor profiles in multiple myeloma. Br J Cancer. 2013;108:1801\u20136. https:\/\/doi.org\/10.1038\/bjc.2013.186.","journal-title":"Br J Cancer"},{"key":"1049_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/hon.3066","volume":"40","author":"JR Berenson","year":"2022","unstructured":"Berenson JR, Kim C, Bujarski S, To J, Spektor TM, Martinez D, et al. A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed\/refractory multiple myeloma patients. Hematol Oncol. 2022;40:906\u201313. https:\/\/doi.org\/10.1002\/hon.3066.","journal-title":"Hematol Oncol"},{"key":"1049_CR30","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-19-1899","volume":"26","author":"JR Berenson","year":"2020","unstructured":"Berenson JR, To J, Spektor TM, Martinez D, Turner C, Sanchez A, et al. A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed\/refractory multiple myeloma. Clin Cancer Res. 2020;26:2346\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1899.","journal-title":"Clin Cancer Res"},{"key":"1049_CR31","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.18593","volume":"200","author":"JR Berenson","year":"2022","unstructured":"Berenson JR, Martinez D, Safiae T, Boccia R, Yang H, Moezi M, et al. Ruxolitinib and methylprednisolone for treatment of patients with relapsed\/refractory multiple myeloma. Br J Haematol. 2022;200:722\u201330.","journal-title":"Br J Haematol"},{"issue":"5","key":"1049_CR32","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/S12185-022-03335-7","volume":"115","author":"GG Loscocco","year":"2022","unstructured":"Loscocco GG, Vannucchi AM. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. Int J Hematol. 2022;115(5):626\u201344. https:\/\/doi.org\/10.1007\/S12185-022-03335-7.","journal-title":"Int J Hematol"},{"issue":"1","key":"1049_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1049_CR34","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1182\/blood-2018-07-858720","volume":"132","author":"L Arcaini","year":"2018","unstructured":"Arcaini L, Cazzola M. Benefits and risks of JAK inhibition. Blood. 2018;132(7):675\u20136. https:\/\/doi.org\/10.1182\/blood-2018-07-858720.","journal-title":"Blood"},{"key":"1049_CR35","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","volume":"127","author":"JR Berenson","year":"2016","unstructured":"Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, et al. CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127:3360\u20138. https:\/\/doi.org\/10.1182\/blood-2015-11-683854.","journal-title":"Blood"},{"key":"1049_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7.","journal-title":"Lancet Oncol"},{"key":"1049_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","volume":"23","author":"D Siegel","year":"2022","unstructured":"Siegel D, Usmani SZ, Quach H, Mateos M-V, Landgren O, Leleu X, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23:65\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(21)00579-9.","journal-title":"Lancet Oncol"},{"key":"1049_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(13)70380-2.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1049_CR39","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(21)00128-5.","journal-title":"Lancet Oncol"},{"key":"1049_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497\u2013503. https:\/\/doi.org\/10.1182\/blood-2016-02-700872.","journal-title":"Blood"},{"key":"1049_CR41","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/nejmoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207\u201319. https:\/\/doi.org\/10.1056\/nejmoa1506348.","journal-title":"N Engl J Med"},{"key":"1049_CR42","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(15)01120-4.","journal-title":"Lancet"},{"key":"1049_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/nejmoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381:727\u201338. https:\/\/doi.org\/10.1056\/nejmoa1903455.","journal-title":"N Engl J Med"},{"key":"1049_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.15504","volume":"183","author":"R Oostvogels","year":"2018","unstructured":"Oostvogels R, Jak M, Raymakers R, Mous R, Minnema MC. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Br J Haematol. 2018;183:60\u20137. https:\/\/doi.org\/10.1111\/bjh.15504.","journal-title":"Br J Haematol"},{"key":"1049_CR45","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1038\/s41375-020-0857-2","volume":"34","author":"J Mikhael","year":"2020","unstructured":"Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, et al. A dose-finding phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed\/refractory multiple myeloma. Leukemia. 2020;34:3298\u2013309. https:\/\/doi.org\/10.1038\/s41375-020-0857-2.","journal-title":"Leukemia"},{"key":"1049_CR46","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1016\/S2665-9913(22)00044-3","volume":"4","author":"MLK Han","year":"2022","unstructured":"Han MLK, Antila M, Ficker JH, Gordeev I, Guerreros A, Bernus AL, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol. 2022;4:e351\u201361. https:\/\/doi.org\/10.1016\/S2665-9913(22)00044-3.","journal-title":"Lancet Rheumatol."},{"key":"1049_CR47","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/nejmoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800\u201310. https:\/\/doi.org\/10.1056\/nejmoa1917635.","journal-title":"N Engl J Med"},{"issue":"1","key":"1049_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","volume":"12","author":"Z Liu","year":"2023","unstructured":"Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12(1):99. https:\/\/doi.org\/10.1186\/s40164-023-00456-5.","journal-title":"Exp Hematol Oncol"},{"key":"1049_CR49","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","volume":"27","author":"H Tamura","year":"2013","unstructured":"Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. Marrow stromal cells induce B7\u2013H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2013;27:464\u201372. https:\/\/doi.org\/10.1038\/leu.2012.213.","journal-title":"Leukemia"},{"issue":"1","key":"1049_CR50","doi-asserted-by":"publisher","first-page":"2083479","DOI":"10.1080\/2162402X.2022.2083479","volume":"11","author":"G Leclercq","year":"2022","unstructured":"Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology. 2022;11(1):2083479. https:\/\/doi.org\/10.1080\/2162402X.2022.2083479.","journal-title":"Oncoimmunology."},{"key":"1049_CR51","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/jcmm.16176","volume":"25","author":"J Pan","year":"2021","unstructured":"Pan J, Deng B, Ling Z, Song W, Xu J, Duan J, et al. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. J Cell Mol Med. 2021;25:1089\u201399. https:\/\/doi.org\/10.1111\/jcmm.16176.","journal-title":"J Cell Mol Med"},{"issue":"9","key":"1049_CR52","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/diagnostics11091534","volume":"11","author":"A Salomon-Perzy\u0144ski","year":"2021","unstructured":"Salomon-Perzy\u0144ski A, Jamroziak K, G\u0142odkowska-Mr\u00f3wka E. Clonal evolution of multiple myeloma: clinical and diagnostic implications. Diagnostics. 2021;11(9):1534. https:\/\/doi.org\/10.3390\/diagnostics11091534.","journal-title":"Diagnostics"},{"key":"1049_CR53","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","volume":"36","author":"K Misund","year":"2022","unstructured":"Misund K, Hofste OP, Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, et al. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. 2022;36:1887\u201397. https:\/\/doi.org\/10.1038\/s41375-022-01597-y.","journal-title":"Leukemia"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01049-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T09:21:46Z","timestamp":1716369706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01049-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]},"assertion":[{"value":"4 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Incyte Corporation (Gaithersburg, MD, USA) through providing the drug ruxolitinib for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James R. Berenson received research funding from Incyte Corporation to conduct the clinical trial, holds equity and receives compensation from ONCOtracker, and receives speaker fees and research grant support from Amgen, Bristol Myers Squibb, Incyte Corporation, Janssen, Karyopharm, and Sanofi. Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina Swift, Benjamin M. Eades, Sean Bujarski, Yohana Sebhat, Rudra Ray, Susanna Kim, Ashley Del Dosso, and Robert Vescio have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was approved by an institutional review board (approval number: MOD00586804) on 19 February, 2020.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients included in this study provided informed consent in accordance with local institutional review board requirements and the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JRB: conceptualization, methodology, formal analysis, investigation, resources, writing - original draft, writing - review and editing, supervision, project administration, funding acquisition; AL: data curation, project administration, investigation; SR: data curation, project administration, investigation; TS: data curation, investigation; RB: investigation, resources; HY: investigation, resources; MM: investigation, resources; SL: investigation, resources; GS: investigation, resources; SE: investigation, resources; MB: project administration, supervision; RS: investigation; BME: investigation; SB: formal analysis, data curation, writing - review; YS: investigation, data management, data curation; RR: investigation, data management, data curation; SK: writing - review and editing; ADD: writing - original draft, writing - review and editing and RV: investigation, resources.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}